Arovella Therapeutics (ASX:ALA) used the stage of the ASX SMIDCaps Conference to underline its ambitions in next-generation cell therapies, positioning its invariant Natural Killer T (iNKT) platform as a potential solution to some of the most pressing challenges facing oncology treatment. …
Arovella showcases iNKT cell therapy platform at ASX SMIDCaps Conference
September 24, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News